Be the first to review this item
Lerivon (Mianserinum, Mianserine) - antidepressant with sedative component. The active substance lerivon - mianserin - belongs to the piperazino-azepine compounds (true tetracyclic), which distinguishes the drug from the tricyclic antidepressants. The chemical structure lerivon no side chain, which determines holinoliticheskoe effect of tricyclic antidepressants. On the effectiveness of antidepressant activity lerivon comparable to other modern antidepressants. This feature is an anxiolytic effect and a positive effect on sleep.
Observe normal caution when assigning lerivon patients with diabetes mellitus (some patients may require correction of hypoglycemic therapy), patients with diseases of the cardiovascular system, kidney and liver failure. During treatment lerivon should refrain from drinking alcohol because of potentiating the action of the latter on the central nervous system. Patients who during treatment lerivon will be marked rise in temperature, sore throat or symptoms of any infection, shows a study of peripheral blood picture. In the absence of holinoliticheskogo product can be used in patients with an enlarged prostate, glaucoma, impaired GI function, but these patients require follow-up. Elderly patients and patients with cardiovascular disease tend to be well tolerated Lerivon. In elderly patients the use lerivon usually does not cause confusion. Patients receiving Lerivon should refrain from potentially hazardous activities that require increased attention and psychomotor speed reactions (especially in the first few days of therapy).
Lerivon not alter the body's response to the on / in the introduction of pressor amines norepinephrine (noradrenaline) and tyramine. Lerivon not affect the antihypertensive effects of propranolol (either alone or in combination with hydralazine, guanethidine or betanidinom). Lerivon no effect on the severity of the hypotensive effect of clonidine and methyldopa as in their one-off and a long reception. There were no clinically significant interaction with the anticoagulant phenprocoumon lerivon. We can not exclude adverse interaction lerivon with MAO inhibitors, so the reception of MAO inhibitors should be discontinued at least 14 days prior to the appointment lerivon.
The mode set individually and adjusted during the treatment, depending on the patient response. Adults appoint an initial daily dose of 30-45 mg. An effective therapeutic dose ranges of 30-90 mg / day. The daily dose can be divided into several stages or, preferably, to assign 1 time overnight (given a positive effect on sleep). It is advisable to continue antidepressant therapy for a few months after the clinical effect. For elderly patients the dose selected individually, starting with 30 mg / day. Then the daily dose may be gradually increased. Supporting effective dose may be somewhat lower than for middle-aged patients. no recommendation due to limited clinical experience with the drug in this category of patients for use in children.
Important notice- the outer box design may vary before prior notice!
Someone from the Malaysia - just purchased the goods:
Zhenoluten 60 capsules